For how we live.
3 articles published between June 9, 2025 and October 3, 2026.
A randomised trial at eight South Korean hospitals found pulse methylprednisolone no better than a non-pulse regimen for surviving an acute exacerbation of idiopathic pulmonary fibrosis.
Jascayd cleared on 7 October under priority review with orphan designation. The phase 3 trial it rests on measured lung function decline, not survival, and most patients were already on an antifibrotic.
Rentosertib was safe over 12 weeks in 71 patients with idiopathic pulmonary fibrosis. A lung-function signal appeared at the highest dose, in a trial not designed to prove efficacy.